News

Camlin Fine Sciences Limited informed the BSE Limited and National Stock Exchange of India Ltd that it received a confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026, from MUFG Intime India Private Limited, formerly Link Intime India Private Limited, its Registrar and Share Transfer Agent.

Camlin Fine Sciences Limited will close its trading window for designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, in compliance with SEBI regulations.

Camlin Fine Sciences Limited announced that its Board of Directors approved the appointment of Mr. Atul Pradhan (DIN: 00171022) as an Additional Non-Executive Independent Director for a term of five years, effective September 11, 2026, subject to shareholder approval. Mr. Pradhan is an IICA-certified Independent Director and former Head of Management Consulting at KPMG India, and is not related to any existing directors.

Camlin Fine Sciences Ltd share price declined by 1.66% to Rs 124.35 after the company`s net profit witnessed a sharp fall of 138.97% to Rs 33.62 crore, while revenue from operations increased sharply by 22.38% to Rs 519.88 crore in Q2FY26 over Q1FY26. The market capitalization of Specialty Chemicals industry group stocks on BSE stood at Rs 5.09 lakh crore, rallying 15.27%. It has marginally improved by 1.74% over last one week and moving up by 12.24% in last one month while the market capitalization of Camlin Fine Sciences Ltd has eased by 4.75% and 4.63% in the same period respectively. Profit before tax (PBT) of Camlin Fine Sciences Ltd stood at Rs 34.09 crore in Q2 FY26, surging by 218.30% year-on-year, and plunging by 142.59% quarter-on-quarter. EBITDA came in at Rs 8 crore, tanking 41.87% YoY and nosediving by 391.91% sequentially. Total expenses surged 24.81% to Rs 529.76 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 312.35 crore, soaring by 158.72% YoY, while employee benefits expense was at Rs 73.43 crore, rising by 11.38% YoY. For the TTM ended FY26, revenue from operations tick up 5.81% to Rs 1723.31 crore, while net profit tumbled by 148.44% to Rs 31.53 crore, compared to previous TTM. EBITDA soared by 20985% to Rs 78.09 crore, and PBT plunged by 149.54% to Rs 31.99 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 82.07 crore in FY26, as against Rs 23.0 crore in FY25. Camlin Fine Sciences Ltd crashed 44.31% in last one year, underperforming the benchmark BSE Sensex which has eased by 2.56% during the same period.

Camlin Fine Sciences will hold a meeting of the Board of Directors of the Company on 11 August 2026.